The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Inhibitory Effect of (−)‐Epigallocatechin‐3‐Gallate on Lipid Accumulation of 3T3‐L1 Cells
Abstract
Objective: The objective of this study was to investigate the molecular mechanisms underlying the attenuating effect of (−)‐epigallocatechin‐3‐gallate (EGCG) on proliferation and lipid accumulation of 3T3‐L1 cells, with a focus on the duration of EGCG treatment. Research Methods and Procedures: Cell viability was measured by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium assay and diamidino‐2‐phenylindole staining. The anti‐adipogenic effect of EGCG on 3T3‐L1 cells was analyzed by glycerol‐3‐phosphate dehydrogenase activity and Oil red O staining. Western blot analysis was used to detect adenosine monophosphate‐activated protein kinase (AMPK) activation and phosphorylation of its substrate, acetyl‐CoA carboxylase (ACC), and expression of insulin (INS) receptor, INS receptor substrate‐1 (IRS‐1), and adipocyte marker proteins. Results: Exposure to EGCG during the early period of adipogenesis (7 days) was sufficient to prevent lipid accumulation. During this period, EGCG greatly decreased expression of the adipocyte marker proteins peroxisome proliferator‐activated receptor γ2 (PPARγ2) and liver X receptor (LXR)‐α. Furthermore, EGCG significantly induced generation of reactive oxygen species (ROS), which led to AMPK activation, and these effects were eliminated by N‐acetylcysteine (NAC) treatment. Also, EGCG increased the tyrosine phosphorylation of INS receptor and INS‐1 with increasing incubation time. In contrast, EGCG treatment did not alter glycerol release in the presence or absence of 2′,5′‐dideoxyadenosine (DDA), indicating that EGCG had no effect on lipolysis. Discussion: Our data demonstrate that EGCG decreased cell viability and inhibited differentiation of 3T3‐L1 cells in a manner dependent on the duration of treatment. Also, we showed that inhibition of adipocyte differentiation by EGCG was associated with decreased glycerol‐3‐phosphate dehydrogenase (GPDH) activity accompanied by a strong inhibition of PPARγ2‐induced transcriptional activity. Furthermore, the inhibition of adipocyte differentiation by EGCG involved generation of ROS and activation of AMPK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426
Browne, G. J., Finn, S. G., & Proud, C. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309773200 · Cited by 353
Cited by
Kim, H.-S., Quon, M. J., & Kim, J.-A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.022 · Cited by 804
The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways
Ahn, J., Lee, H., Kim, S., Park, J., & Ha, T. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.077 · Cited by 522
Self-citationQuercetin and metabolic syndrome: A review
Hosseini, A., Razavi, B. M., Banach, M., & Hosseinzadeh, H. (2021) · Phytotherapy Research · doi:10.1002/ptr.7144 · Cited by 386
Anti-obesogenic and antidiabetic effects of plants and mushrooms
Martel, J., Ojcius, D. M., Chang, C.-J., Lin, C.-S., Lu, C.-C., Ko, Y.-F., Tseng, S.-F., Lai, H.-C., & Young, J. D. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.142 · Cited by 266
Yoon, J. Y., Kwon, H. H., Min, S. U., Thiboutot, D. M., & Suh, D. H. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.292 · Cited by 183
Metadata
- Authors
- Moon, H., Chung, C., Lee, H., Kim, T., Choi, Y., & Cho, C.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 15
- Issue
- 11
- Pages
- 2571-2582
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2151385330
- Cited by
- 220
- References
- 3
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.